Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CG5503 IR; tapentadol · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| CG5503 IR; tapentadol | DRUG | - |
Inclusion Criteria: * Clinical diagnosis of chronic osteoarthritis of the hip or the knee based on clinical and radiographic (X-Ray) criteria defined by standard accepted guidelines * candidate (qualifies) for primary one-sided total or partial joint replacement surgery due to noninflammatory, end-...
CG5503 IR (tapentadol) is an investigational small molecule being studied for the treatment of arthralgia and osteoarthritis. It is being evaluated in patients awaiting joint replacement surgery and in the treatment of acute pain from bunionectomy. The drug is in Phase 3 clinical development.
CG5503 IR (tapentadol) is being developed by Johnson & Johnson (NYSE: JNJ). The company is conducting Phase 3 clinical trials to evaluate the drug's effectiveness and safety in patients with osteoarthritis and arthralgia.
CG5503 IR (tapentadol) is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 3 trials have been completed, one in patients awaiting joint replacement surgery and another in patients with acute pain from bunionectomy.
CG5503 IR (tapentadol) has completed two Phase 3 clinical trials. NCT00361582 evaluated multiple doses in 669 patients awaiting joint replacement surgery for osteoarthritis. NCT00364247 evaluated the drug in 602 patients with acute pain from bunionectomy compared with placebo, followed by an open-label extension.
Yes, CG5503 IR is the same drug as tapentadol. The name CG5503 IR refers to the immediate-release formulation of tapentadol, which is being studied in Phase 3 clinical trials for the treatment of arthralgia and osteoarthritis.